TORONTO, Sept. 27, 2017 /CNW/ - SQI Diagnostics Inc.
("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today announced that Dr. Eric Brouwer,
Ph.D, has joined SQI as the Chief Scientific Officer ("CSO"). In this capacity, he will be responsible for
developing and executing the Company's Research and Development programs. This includes leading all aspects of the product
development process and the development of the Company's expanding product pipeline. He will also serve as an important interface
with our key clients and partners.
SQI is a Toronto-based life sciences and diagnostics company that develops and commercializes
proprietary technologies and products for advanced multiplexed diagnostics.
Dr. Brouwer is an accomplished leader in the life sciences sector, with experience in assay design and development,
product launch, clinical studies and regulatory submissions. He was most recently the Chief Scientific Officer of Trinity
Biotech, of Bray, Ireland, and CEO of Trinity Biotech's Swedish subsidiary, Fiomi Diagnostics
AB. Trinity Biotech develops, manufactures and markets diagnostics products in autoimmune disease, cardiac markers,
infectious disease, and point of care tests.
Before working at Trinity, Dr. Brouwer was employed at Abbott Laboratories for 15 years and held progressively senior
positions leading Assay Research and Development in Point of Care diagnostics lastly serving as Director, Assay Research and
Development.
Dr. Brouwer received his Ph.D. in Chemistry from Carleton University in Ottawa and served there as Adjunct Chemistry Professor from 2000 to 2005.
"SQI presents an exciting opportunity for me to bring my years of experience in assay development to an innovator in the life
sciences market," said Dr. Eric Brouwer. "I am looking forward to joining the team that
delivers SQI's commercial and technological goals."
"We are very pleased to have Dr. Brouwer join us at this very exciting time in our corporate development," said Andrew Morris, CEO of SQI Diagnostics. "Eric brings a combination of product launching, scientific and
leadership skills that will help propel SQI to the next level."
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops clinical grade multiplexed microarray and
molecular assays run on its automated instrumentation for the pharmaceutical research, animal health, and clinical diagnostics
markets. SQI develops custom research and diagnostic assays that are multiplexed; meaning the simplification, consolidation and
automation of many individual tests into one. This increases sample throughput, reduces time, cost and chance for human error,
and provides excellent data quality. For more information, please visit sqidiagnostics.com.
Sales and Marketing Contact:
Vice President, Global Commercial Operations
Russ Peloquin
913.484.9022
rpeloquin@sqidiagnostics.com
Investor Relations Contacts:
Chief Executive
Officer
Andrew
Morris
416.674.9500 ext.
229
amorris@sqidiagnostics.com
Vice President, Finance and Administration
Patricia Lie
416.674.9500 ext. 277
plie@sqidiagnostics.com
Forward-looking Statements
This press release contains certain statements including, without limitation, the words "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect", "believe", "in the process", "benefits", "leading to", "position" "possible", "is
subject to" and other similar expressions which may constitute "forward-looking statements" within the meaning of applicable
securities laws. Forward-looking statements reflect the Company's current expectations and assumptions, and are subject to a
number of risks and uncertainties that could cause actual results to differ materially from those anticipated. Readers are
cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and
uncertainties including, but not limited to: our ability to market and sell our products including our novel multiplexing
technologies and detection platforms; our ability to maintain any technical or product advantages; the success of our
Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business; the successful
regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic consumable kits; adverse
changes in general economic conditions; international risk and currency exchange fluctuations; competitor activity; technology
changes; regulatory approvals and the impact of healthcare reform legislation; and, SQI's ability to raise additional funds in
the future.
Such statements, risks and uncertainties are detailed in the Company's ongoing filings with the securities regulatory
authorities, and are available to the public at www.sedar.com . The Company undertakes no obligation to publicly update or revise any forward-looking
statements either as a result of new information, future events or otherwise, except as required by applicable securities
laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE SQI Diagnostics Inc.
View original content: http://www.newswire.ca/en/releases/archive/September2017/27/c3789.html